How is angiotensin 1-7 related to angiotensin II?

Angiotensin 1-7 is produced by enzymatic cleavage of angiotensin II by ACE2. It acts as a physiological counterbalance to angiotensin II: while angiotensin II causes vasoconstriction, inflammation, and fibrosis via AT1 receptors, angiotensin 1-7 promotes vasodilation, anti-inflammation, and anti-fibrosis via the Mas receptor.

Why did angiotensin 1-7 gain attention during the COVID-19 pandemic?

ACE2, which generates angiotensin 1-7, is the cell surface receptor used by SARS-CoV-2 for entry. It was hypothesized that viral binding to ACE2 reduces its enzymatic activity, depleting protective angiotensin 1-7 and tipping the RAAS balance toward pro-inflammatory angiotensin II effects. This contributed to interest in exogenous angiotensin 1-7 as a potential therapy, though clinical evidence remains lacking.

Is angiotensin 1-7 available as a therapy?

No. Angiotensin 1-7 has no approved therapeutic use in any country. Its extremely short half-life and lack of human clinical trial data are major barriers to development. It is available only as a research-grade peptide.

What is the recommended dose range for Angiotensin 1-7?

The research dose range is 0.1–1.0 mcg/kg/min in preclinical protocols, administered via Intravenous infusion, Continuous.

peptide dosing

Angiotensin 1-7 Dosing & Reconstitution Guide

Complete dosing reference for Angiotensin 1-7 (Cardiovascular / Vasoactive). Covers reconstitution, dose range, titration schedule, pharmacokinetics, and storage protocols for research use.

Dosing Protocol

Route: Intravenous infusion Frequency: Continuous Dose Range: 0.1–1.0 mcg/kg/min in preclinical protocols

Safety & Contraindications

Safety: No human safety data from controlled clinical trials Hypotension is the expected pharmacological effect and primary risk Extremely short plasma half-life necessitates continuous infusion or formulation modification for any therapeutic application

Contraindications: Not approved for human use; no formal contraindication labeling exists; Theoretical risk of hypotension in volume-depleted or hemodynamically unstable patients

Related Research News

Regulatory

Aclerastide: Effective Therapy for Diabetic Foot Ulcers

Aclerastide, an analog of angiotensin 1-7, shows strong potential in treating diabetic foot ulcers through progenitor proliferation, vascularization, collagen deposition, and re-epithelialization. Preclinical studies demonstrate its superiority over existing topical growth factors, with Phase II trials confirming faster wound closure lasting up to 20 weeks. Phase III trials are now recruiting patients.

May 12, 2026

Peptide Tools

Reconstitution CalculatorCalculate concentration and syringe units for any peptide vial with visual syringe guide.

Dosage & Cycle PlannerPlan a multi-week peptide cycle. Calculate total supply needed and vial counts.

Bacteriostatic Water CalculatorCalculate how many vials of bacteriostatic water you need for your peptide stack.

Cost-Per-Milligram CalculatorCompare vendors side-by-side. Find the best value per milligram and per dose.

Frequently Asked Questions

Related Resources

Browse All Research Peptides

Explore More

Angiotensin 1-7 Dosing Guide Peptides for Research Peptides for Cardiovascular Biology

Research Use Only. The information on this page is compiled from published research literature and is provided for educational purposes only. It does not constitute medical advice. All compounds referenced are intended for in vitro research use by qualified laboratories and institutions.